Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.86 |
| ▸ | PPARA | Q07869 | 1/20 | 0.86 |
| ▸ | NPC1 | O15118 | 4/20 | 0.81 |
| ▸ | RAB9A | P51151 | 4/20 | 0.81 |
| ▸ | POLB | P06746 | 4/20 | 0.81 |
| ▸ | GLS | O94925 | 6/20 | 0.78 |
| ▸ | GLS2 | Q9UI32 | 5/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | ATM | Q13315 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18545405 | 1.00 | NR1H4 (0.86) | NR1H4PPARANPC1RAB9APOLB | |
| SCHEMBL13846877 | 0.93 | NR1H4 (1.00) | NR1H4PPARANPC1RAB9APOLB | |
| SCHEMBL8193139 | 0.88 | RAB9A (1.00) | NR1H4PPARANPC1RAB9APOLB | |
| SCHEMBL8193149 | 0.88 | RAB9A (1.00) | NR1H4PPARANPC1RAB9APOLB | |
| SCHEMBL1249980 | 0.87 | POLB (0.77) | NR1H4PPARANPC1RAB9APOLB | |
| SCHEMBL12892002 | 0.87 | POLB (0.77) | NR1H4PPARANPC1RAB9APOLB | |
| SCHEMBL1249981 | 0.87 | POLB (0.77) | NR1H4PPARANPC1RAB9APOLB | |
| SCHEMBL14325640 | 0.86 | RAB9A (0.68) | NR1H4PPARANPC1RAB9APOLB | |
| SCHEMBL13846851 | 0.83 | NR1H4 (0.64) | NR1H4PPARANPC1RAB9APOLB | |
| SCHEMBL13846859 | 0.80 | NPC1 (0.69) | NR1H4PPARANPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | NR1H4 391/4885PPARA 1190/4885NPC1 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.